U.S. FDA approves ADUHELM™ (aducanumab-avwa) for Alzheimer’s disease

Biogen and Eisai receive FDA accelerated approval for a new therapy targeting amyloid beta plaque.

From the CEO

"We come to this historic moment with thanks for the inspiring contributions of thousands of Alzheimer’s patients and caregivers who participated in our clinical trials, for the pioneering work of scientists and researchers inside and outside Biogen, and for the relentless dedication of our employees globally."
Read the full letter »

Visit the Biogen newsroom.

NEWS & MEDIA »

Alzheimer's News Updates

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

Read more»

An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

Read more»

Media Statement on Aduhelm™

Responding to questions about post-marketing requirement and patient access.

Read more»

Commitment to access and health equity

Biogen and Eisai are committed to providing access to ADUHELM for patients across a spectrum of financial situations.

 

For patients facing difficulty affording ADUHELM, financial assistance programs are available. Personal Biogen Support Service Coordinators are now available to patients and their families to provide one-on-one support. The service coordinators can answer questions about Alzheimer’s disease and ADUHELM treatment, assess financial assistance options for eligible patients, and locate healthcare providers and infusion sites, among other topics. Biogen Support Service Coordinators can be reached at 1-833-425-9360.

 

Biogen and Eisai are also committed to addressing health equity for underserved and underrepresented populations that are at higher risk for Alzheimer’s disease. Initiatives aim to help patients and their families understand the disease, navigate the diagnostic journey, secure culturally competent care and afford treatment.

  READ MORE »

Learn more about Biogen's pricing principles.

Patient inquiries

Biogen Support Services
833-425-9360

Alzheimer's Learning Line
833-LRN-LINE (833-576-5463)

Sign up to receive more news and updates from Biogen »

* This content is intended for U.S. audiences only